摘要
痛风病是与高尿酸血症、尿酸盐沉积密切相关的慢性、进展性、致残性代谢疾病.本文旨在系统梳理痛风病各阶段相关的中医药古籍记载,厘清其中医药认识发展脉络,明确各时期对痛风病的认知及其特点,为痛风病深入研究和临床防治提供中医药理论支撑.通过查阅先秦至明清时期中医医论、方书、本草及医案106部,从中归纳整理有关痛风病的中医药认识,包括病名、症状、病因病机及治疗用药等,探析其发展源流.先秦时期,中医药古籍零星记载了痛风病各阶段的症状、病名和(或)病因病机;汉至隋唐,医家在扩充病名、症状及病因病机的基础上,提出了多种内外治法,标志着痛风病理论形成;宋元明清,证候分型、鉴别诊断及饮食禁忌等论述丰富了这一理论.中医药对痛风病的认识萌芽于先秦,理论形成于汉至隋唐,丰富发展于宋元明清,逐渐形成了一套较为全面的痛风病中医理论体系.
Abstract
Gout is a chronic,progressive,and disabling metabolic disease closely related to hyperuricemia and urate deposition.This article aimed to systematically review the records of gout at various stages in ancient Chinese medical texts,clarify the develop-ment of traditional Chinese medicine(TCM)understanding,and outline the knowledge and characteristics of gout during different periods,thereby providing TCM theoretical support for in-depth research and clinical prevention and treatment of gout.By reviewing 106 TCM texts,including medical theories,prescriptions,materia medica,and medical cases from the pre-Qin to the Ming and Qing dynasties,the TCM understanding of gout was summarized,including disease names,symptoms,etiology and pathogenesis,and treat-ment methods,to explore its developmental origins.In the pre-Qin period,TCM texts sporadically recorded symptoms,disease names,and(or)etiology and pathogenesis of gout at various stages.From the Han to the Sui and Tang dynasties,medical practition-ers expanded on disease names,symptoms,and etiology and pathogenesis,and proposed various internal and external treatments,marking the formation of gout theory.During the Song,Yuan,Ming,and Qing dynasties,discussions on syndrome differentiation,dif-ferential diagnosis,and dietary taboos enriched this theory.TCM understanding of gout began in the pre-Qin period,with theoretical formation from the Han to the Sui and Tang dynasties,and further development during the Song,Yuan,Ming,and Qing dynasties,gradually forming a relatively comprehensive TCM theoretical system for gout.
基金项目
国家自然科学基金联合基金项目(U20A20406)
国家中医药领军人才支持计划"岐黄学者"项目(1040063320004)
张冰全国名老中医药专家传承工作室建设项目(国家中医药人教函[2022]75)
维普
万方数据